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Purpose: Dual therapy with bronchodilators of different pharmacological classes may produce greater
lung function improvements than either drug alone. However, the relationship between a patient's
response to monotherapy and response to dual bronchodilator therapy is currently unknown. We aimed
to investigate whether dual therapy with umeclidinium/vilanterol provides additional beneﬁt over
umeclidinium or vilanterol monotherapy in patients with chronic obstructive pulmonary disease (COPD)
identiﬁed as responsive (increase from baseline in forced expiratory volume in 1s [FEV1] of 12% and
200 mL, Day 1) or non-responsive to monotherapy.
Methods: In two randomised, double-blind, three-way complete-block, cross-over studies (DB2116132
n ¼ 207; DB2116133 n ¼ 182; intent-to-treat), all patients (moderate-to-very severe COPD) were
randomised to 1 of 6 sequences and received once-daily umeclidinium 62.5mcg, vilanterol 25mcg, and
umeclidinium/vilanterol 62.5/25mcg (one treatment/14-day period; 10e14-day washout). Key endpoints
were 0e6 h weighted mean FEV1 (Day 14) and trough FEV1 (Day 15). Adverse events, vital signs and
COPD exacerbations were assessed. Pooled data are presented.
Results: Umeclidinium/vilanterol signiﬁcantly (p  0.001, unless stated otherwise) increased 0e6 h
weighted mean FEV1 versus umeclidinium in umeclidinium-responders (þ114 mL), versus vilanterol in
vilanterol-responders (þ92 mL) and versus umeclidinium (þ70 mL) and vilanterol (þ62 mL) in non-
responders. Improvements in trough FEV1 occurred with umeclidinium/vilanterol versus umeclidinium
in umeclidinium-responders (þ77 mL), versus vilanterol in vilanterol-responders (þ86 mL), and versus
umeclidinium (þ42 mL [p ¼ 0.020]) and vilanterol (þ58 mL) in non-responders. All treatments were well
tolerated.
Conclusions: Once-daily umeclidinium/vilanterol signiﬁcantly improved lung function in patients with
COPD, with quantitatively greater improvements in patients identiﬁed as responders to umeclidinium
and vilanterol monotherapy than non-responders.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).sis of covariance; BMI, body mass index; CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; ECG,
1 second; FVC, forced vital capacity; GOLD, Global initiative for chronic Obstructive Lung Disease; ITT, intent-to-treat;
A, long-acting muscarinic antagonist; MCID, minimally clinically important difference; NA, not analysed; SD, standard
I, vilanterol; wm, weighted mean.
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The long-acting muscarinic antagonist (LAMA) umeclidinium
(UMEC) is approved both as a monobronchodilator and in
combination with the long-acting beta2-agonist (LABA)
vilanterol (VI) for maintenance treatment of chronic obstructive
pulmonary disease (COPD) in the US, EU and several other
countries [1e4]. The scientiﬁc concept underlying dual bron-
chodilator treatment is that using two bronchodilators with
different mechanisms of action will lead to additive clinical
beneﬁts [5]. Parallel group studies in patients with COPD have
demonstrated that UMEC/VI signiﬁcantly improved lung
function versus placebo [6,7] and versus each monotherapy
component [6e8].
The therapeutic response to all bronchodilators varies between
patients [5]. An important point of interest for using LAMA/LABA
combinations, including UMEC/VI, in clinical practice is identifying
patient subgroups likely to gain themost beneﬁt from dual therapy.
The absolute magnitude of clinical beneﬁt with a dual combination
may be related to the individual response to the component
monotherapies. Similarly, the additional beneﬁt of adding a second
bronchodilator to monotherapy may be related to individual
responsiveness to monotherapy. We have therefore investigated
the relationships between monobronchodilator therapy and dual
therapy responses within the same patient.
We conducted two, three-way, complete block cross-over studies,
comparing the improvement in lung function with once-daily
UMEC/VI 62.5/25mcg with that of its monotherapy components, in
subgroups of patients with COPD, based on response to mono-
therapy with UMEC 62.5mcg and VI 25mcg. The aim of these studies
was to investigate whether individual lung function responses to
long-acting bronchodilator monotherapy predict the response to
dual bronchodilator treatment, in terms of the absolute effect size
and the additive beneﬁt achieved. Preliminary results from the238 patients 
enrolled
207 randomised
202 received 
UMEC 62.5mcg
once daily
202 received 
UMEC/VI 62.5/25mcg 
once daily
20 withdrew during pre-screen period
10 screening failures
8 did not meet inclusion/exclusion criteria
2 withdrew consent
1 run-in failure
1 adverse event
7 withdrawn during
treatment period
196 completed 199 completed
ITT population, n = 207
200 received 
VI 25mcg 
once daily
196 completed
4 withdrawn during
treatment period
3 withdrawn during
treatment period
1 withdrawn during
washout*
Analysis: per protocol, n = 201
Overall, 192 patients completed the study. Primary reasons for withdrawal (n): 
AEs (2), lack of efficacy (3), protocol deviation (5), withdrew consent (5)
a
Fig. 1. Flow diagram for disposition of patients (CONSORT) for a) DB2116132 and b) DB21161
a patient was considered to have completed the treatment period if they had a Day 15 visit in
in the study; therefore, they were not counted as a completer for that period.individual studies have been previously presented at the European
Respiratory Society Annual Congress in Munich in 2014 [9].
2. Methods
2.1. Study design and patients
Both studies were phase IIIb, multicentre, randomised, double-
blind, three-way, complete block, cross-over trials (GSK study/
www.clinicaltrials.gov numbers: DB2116132/NCT02014480;
DB2116133/NCT01716520). DB2116132 was conducted in Slovakia
and Ukraine (23 centres; 5 February 2013 to 11 June 2013).
DB2116133 was conducted in Germany and Estonia (21 centres;
19 October 2012 to 6 March 2013).
Eligible patients had moderate-to-very-severe COPD [10] with a
pre- and post-salbutamol forced expiratory volume in 1s (FEV1)/
forced vital capacity (FVC) ratio <0.70 and FEV1  70% predicted
normal. Other key inclusion criteriawere: age40 years; current or
former (stopped smoking for 6 months) cigarette smokers with a
history of 10 smoking pack-years. Key exclusion criteria were:
asthma/other known respiratory disorders; hospitalisation for
COPD or pneumonia within 12 weeks of screening.
Studies were approved by local ethics committees and con-
ducted in accordance with the Declaration of Helsinki [11] and
Good Clinical Practice guidelines [12]. Written informed consent
was obtained from all patients.
2.2. Randomisation and treatment
Patients were randomised equally to 1 of 6 treatment sequences
dispensed using a Registration and Medication Ordering System
(GSK, Brentford, UK).
Patients received each of three treatments in a random order:
UMEC 62.5mcg (delivered dose 55mcg; GSK, London, UK), VIb
207 patients 
enrolled
182 randomised
171 received 
UMEC 62.5mcg
once daily
173 received 
UMEC/VI 62.5/25mcg 
once daily
9 withdrew during pre-screen period
10 screening failures
9 did not meet inclusion/exclusion criteria
1 withdrew consent
6 run-in failures
4 did not meet continuation  criteria
2 withdrew consent
164 completed 168 completed
ITT population, n = 182
171 received 
VI 25mcg 
once daily
169 completed
4 withdrawn during
treatment phase
4 withdrawn during
washout*
Analysis: per protocol, n = 173
2 withdrawn during
treatment phase
5 withdrawn during
washout*
7 withdrawn during
treatment phase
1 withdrawn during
washout*
Overall, 159 patients completed the study. Primary reasons for withdrawal (n): 
AEs (6), lack of efficacy (4), protocol deviation (1), met stopping criteria (7), withdrew consent (5)
33. *Patients withdrawing during washout are counted under the last treatment taken;
that period; zone patient did not attend Day 15 of that treatment period but continued
Table 1
Patient demographics and lung function at baseline (ITT population).
DB2116132
(n ¼ 207)
DB2116133
(n ¼ 182)
Pooled
(n ¼ 389)
Age, mean ± SD, years 60.5 ± 7.99 63.2 ± 8.19 61.8 ± 8.18
Male, n (%) 169 (82) 127 (70) 296 (76)
BMI, mean ± SD (range), kg/m2 27.18 ± 4.596
(17.6e43.0)
27.53 ± 4.953
(16.4e45.0)
27.34 ± 4.763
(16.4e45.0)
White race, n (%) 207 (100) 182 (100) 389 (100)
Smoking history and status
Current smoker, n (%) 115 (56) 100 (55) 215 (55)
Years smoked, mean ± SD (range) 33.0 ± 10.44
(10e60)
37.6 ± 9.54
(13e62)
35.2 ± 10.28
(10e62)
No. of cigarettes/day, mean ± SD (range) 18.7 ± 4.43
(6e40)
21.9 ± 10.61
(5e80)
20.2 ± 8.09
(5e80)
Smoking pack years, mean ± SD (range) 30.8 ± 12.21
(10e80)
41.3 ± 23.78
(10e172)
35.7 ± 19.25
(10e172)
COPD history
Duration of COPD, n (%), years
<1 1 (<1) 4 (2) NA
1e<5 59 (29) 64 (35) NA
5e<10 70 (34) 56 (31) NA
10 77 (37) 58 (32) NA
COPD type, n (%)a
Chronic bronchitis 163 (79) 152 (84) NA
Emphysema 123 (59) 80 (44) NA
COPD exacerbation history 12 months prior to screening, n (%)
Required oral/systemic corticosteroids and/or antibiotics (not involving hospitalisation)
0 119 (57) 156 (86) 275 (71)
1 66 (32) 22 (12) 88 (23)
2 19 (9) 4 (2) 23 (6)
>2 3 (1) 0 3 (<1)
Required hospitalisation
0 128 (62) 179 (98) 307 (79)
1 56 (27) 3 (2) 59 (15)
2 23 (11) 0 23 (6)
Screening lung function, mean (SD)
Pre-bronchodilator FEV1, L 1.354 (0.4732) 1.297 (0.4054) 1.328 (0.4431)
Post-salbutamol FEV1, L 1.454 (0.4936) 1.466 (0.4249) 1.460 (0.4622)
Post-ipratropium FEV1, L 1.522 (0.5104)d 1.554 (0.4487) 1.537 (0.4820)e
Post-salbutamol percent predicted FEV1, % 45.1 (13.14) 47.8 (11.19) 46.4 (12.32)
Percent reversibility to salbutamol, % 8.2 (11.73) 14.4 (13.32) 11.1 (12.86)
Reversibility to salbutamol, mL 99.0 (141.41) 169.6 (140.09) 132 (144.98)
Percent reversibility to salbutamol and ipratropium, % 14.0 (15.25)d 21.5 (16.53) 17.5 (16.28)e
Reversibility to salbutamol and ipratropium, mL 168.0 (183.57)d 256.9 (179.17) 209.8 (186.65)e
GOLD stage (percent predicted FEV1), n (%)
Stage I (80%) 0 0 0
Stage II (50% to <80%) 83 (40) 80 (44) 163 (42)
Stage III (30% to <50%) 95 (46) 91 (50) 186 (48)
Stage IV (<30%) 29 (14) 11 (6) 40 (10)
Reversibility, n (%)
Reversible to salbutamolb 32 (15) 71 (39) 103 (26)
Reversible to salbutamol and ipratropiumc 73 (36)d 105 (58) 178 (46)e
Current medical condition in 20% of patients, n (%)
Any condition 162 (78) 153 (84) NA
Cardiovascular risk factors 105 (51) 111 (61) NA
Hypertension 98 (47) 99 (54) NA
Hyperlipidaemia 17 (8) 44 (24) NA
Cardiac disorders 74 (36) 22 (12) NA
Musculoskeletal disorders 36 (17) 45 (25) NA
BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1s; GOLD, Global initiative for chronic Obstructive Lung Disease; ITT,
intent-to-treat; NA, not analysed; SD, standard deviation; UMEC, umeclidinium; VI, vilanterol.
a Patients could select chronic bronchitis, emphysema or both.
b Reversible was an increase in FEV1 of12% and200mL following administration of salbutamol. Non-reversible was an increase in FEV1 of<200mL or a200mL increase
that was <12% from pre-salbutamol FEV1.
c Reversible was an increase in FEV1 of12% and200mL following administration of both salbutamol and ipratropium. Non-reversible was an increase in FEV1 of<200mL
or a 200 mL increase that was <12% from pre-salbutamol FEV1.
d n ¼ 205.
e n ¼ 387.
J.F. Donohue et al. / Respiratory Medicine 112 (2016) 65e74 6725mcg (delivered dose 22mcg; GSK, London, UK) and UMEC/VI
62.5/25mcg (delivered dose 55/22mcg; GSK, London, UK). These
once-daily treatments were administered via the ELLIPTA®1 dry1 ELLIPTA® is a trademark of the GlaxoSmithKline group of companies.powder inhaler for 14 days with a 10e14-day washout between
each treatment. Baseline spirometry was deﬁned as the mean value
obtained from the 30 min and 5 min assessments on Day 1.
Serial spirometry assessments were conducted on Day 1 and Day
14. Measurements were obtained 15 min, 30 min, 1 h, 3 h and 6 h
after morning dosing. Trough spirometry was obtained at clinic
sisylanapuorgbus-ruofcoh-tsoPsisylanayramirP
Day 1 response Categorisaon Day noitasirogetaCesnopser1
UMEC ylno -CEMU responder 
(n = 173)
UMEC ylno CEMU responder 
(n = 67)
UMEC + VI UMEC and IV CEMU + VI responder 
(n = 106)
VI yln -IV responder o
(n = 185)
VI ylno IV responder
(n = 79)
No UMEC or VI response Non-responder 
(n = 118)
No UMEC or VI response Non-responder
(n = 118)
Fig. 2. Treatment comparisons investigated in primary analysis and in post-hoc four-subgroup analysis. UMEC, umeclidinium; VI, vilanterol.
J.F. Donohue et al. / Respiratory Medicine 112 (2016) 65e7468visits on Day 2, Day 14 and Day 15 of each treatment period, with
measurements taken 23 and 24 h after the previous morning
dosing (see Supplementary Methods for further details of ran-
domisation and treatment).2.3. Outcome measures
The primary endpoint was weighted mean (wm) FEV1 over
0e6 h post-dose on Day 14 of each treatment period, and the key
secondary endpoint was trough FEV1 on Day 15. Data from studies***
***
UMEC
62.5mcg
n = 169
VI
25mcg
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Fig. 3. Primary analysis of 0e6 h wmFEV1 on Day 14 (panels aec) and trough FEV1 on Day 1
VI-respondersb (panel b and e) or non-responders to UMEC and VI (panel c and f) on Day 1
both monotherapies (calculated by combining the LS mean change from baseline observed
monotherapy effect but less than the combined total effect of both monotherapies, a fully ad
responder: responder to UMEC monotherapy or responder to both UMEC monotherapy and
monotherapy and UMEC monotherapy. *p ¼ 0.020 for UMEC/VI versus UMEC in non-respon
UMEC and VI (panel f) ***p < 0.001 for: UMEC/VI versus UMEC in UMEC responders (panels
and versus VI in non-responders to UMEC and VI (panel c) FEV1, forced expiratory volume in
vilanterol; wm, weighted mean.DB2116132 and DB2116133 were pooled for these analyses. Other
secondary endpoints were: proportion of patients responsive to
UMEC/VI, UMEC, or VI on Day 1 (FEV1 increase from baseline of
12% and 200 mL at any time 0e6 h post-dose), and proportion
of patients who had a larger change from baseline in 0e6 h
wmFEV1 on Day 14 with UMEC/VI versus each monotherapy.
Additional endpoints are described in the Supplementary Methods.
Safety assessments included adverse events (AEs), vital signs and
COPD exacerbations. Twelve-lead electrocardiograms (ECGs) and
clinical laboratory tests (haematology and clinical chemistry) were***
***
***
*
***
**
VI
25mcg
n = 179
UMEC/VI
62.5/25mcg
n = 180
UMEC
62.5mcg
n = 116
VI
25mcg
n = 116
UMEC/VI
62.5/25mcg
n = 116
0.4
0.3
0.2
0.1
0.0
VI
25mcg
n = 179
UMEC/VI
62.5/25mcg
n = 179
UMEC
62.5mcg
n = 115
VI
25mcg
n = 116
UMEC/VI
62.5/25mcg
n = 115
0.4
0.3
0.2
0.1
0.0
c
f
5 (panels def) according to whether patients were UMEC-respondersa (panel a and d),
(pooled data, ITT population). Grey bars represent the expected fully additive effect of
for the UMEC and VI monotherapies). An additive effect is deﬁned as more than either
ditive effect is deﬁned as equal to the combined effect of both monotherapies. aUMEC-
VI monotherapy; bVI-responder: responder to VI monotherapy or responder to both VI
ders to UMEC and VI (panel f) **p ¼ 0.001 for UMEC/VI versus VI in non-responders to
a and d); UMEC/VI versus VI in VI responders (panels b and e); UMEC/VI versus UMEC
1s; ITT, intent-to-treat; LS, least squares; SE, standard error; UMEC, umeclidinium; VI,
J.F. Donohue et al. / Respiratory Medicine 112 (2016) 65e74 69evaluated in DB2116133 only.2.4. Statistical analyses
Patients were classiﬁed as responders or non-responders ac-
cording to bronchodilator response on Day 1; a responder had an
FEV1 increase from baseline of 12% and 200 mL at any time
0e6 h post-dose on Day 1. Patients without data were classiﬁed as
‘missing’. For 0e6 h wmFEV1 (Day 14) and trough FEV1 (Day 15),
patients who were responders to UMEC only and patients who
were responders to both UMEC and VI were considered UMEC-
responders. Similarly, patients who were responders to VI only
and those who were responders to both UMEC and VI were
considered VI-responders.
In addition, a post-hoc four-subgroup analysis of both primary
and secondary endpoints was conducted in responders to UMEC
only, responders to VI only, responders to both UMEC and VI, and
non-responders No adjustments for multiplicity were performed in
these analyses of pooled data. See Supplementary Methods for
other statistical methods and sample size calculations.3. Results
In DB2116132, of 238 enrolled patients, 207 were in the intent-
to-treat (ITT) population and 192 (93%) completed the study
(Fig. 1a). In DB2116133, 207 patients were enrolled, the ITT popu-
lation consisted of 182 patients and 159 (87%) completed the study
(Fig. 1b). Fig. 1 summarises withdrawal reasons.Table 2
Analysis of 0e6 h wmFEV1 on Day 14 in the overall population and stratiﬁed by UMEC a
Status UMEC
62.5mcg (n ¼ 373)
Overall populationa
n 361
LS mean change (SE) 0.125 (0.0092)
UMEC/VI versus monotherapy
Difference 0.109
(95% CI) (0.090,0.127)
p-value <0.001
Stratiﬁed by UMEC and VI response on Day 1b
UMEC-respondersc
n 169
LS mean change (SE) 0.187 (0.0123)
UMEC/VI versus monotherapy
Difference 0.114
(95% CI) (0.086,0.142)
p-value <0.001
VI-respondersd
n 177
LS mean change (SE) 0.163 (0.0177)
UMEC/VI versus monotherapy
Difference e
(95% CI) e
p-value e
Non-responders
n 116
LS mean change (SE) 0.044 (0.0145)
UMEC/VI versus monotherapy
Difference 0.070
(95% CI) (0.038,0.103)
p-value <0.001
ANCOVA, analysis of covariance; CI, conﬁdence interval; FEV1, forced expiratory volume i
VI, vilanterol; wm, weighted mean.
a Analysis performed using an ANCOVA model with covariates of study, treatment, pe
b Analysis performed using an ANCOVA model with covariates of study, treatment, per
interaction.
c Responder to UMEC: responder to UMEC monotherapy or responder to both UMEC
d Responder to VI: responder to VI monotherapy or responder to both VI monotherapPatient demographics and baseline characteristics were gener-
ally consistent between studies (Table 1). Lung functionwas similar
in both studies, with most patients having moderate-to-severe
COPD; although 14% (DB2116132) and 6% (DB2116133) of patients
had very severe COPD (FEV1% predicted <30%). More patients were
found to be reversible as deﬁned by FEV1>12% and 200 mL post-
salbutamol and post-salbutamol/ipratropium, respectively, in the
DB2116133 study (39% and 58%) than the DB2116132 study (15%
and 36%). More patients in DB2116132 experienced COPD exacer-
bations in the year prior to screening versus DB2116133. Baseline
reversibility to short-acting bronchodilators was lower in
DB2116132 versus DB2116133. COPD medication is summarised
online (Table A1). Treatment compliance in all groups was very
high (Supplementary Results).3.1. Summary of treatment response (Day 1)
In the primary analysis, 173 patients were UMEC-responders,
185 were VI-responders and 118 were non-responders; 19 pa-
tients had missing data (either missing both monotherapy treat-
ments or was a non-responder to one monotherapy and missing
the other treatment) (Fig. 2). In the additional post-hoc four-sub-
group analysis, there were 67 responders to UMEC only, 79 re-
sponders to VI only, 106 responders to both UMEC and VI, and 118
non-responders (Fig. 2). Proportions of patients in each response
category were generally similar between studies (Supplementary
Results).nd VI response on Day 1, Pooled analysis (ITT population).
VI
25mcg (n ¼ 371)
UMEC/VI 62.5/25mcg
(n ¼ 375)
362 366
0.146 (0.0093) 0.234 (0.0092)
0.088 e
(0.070,0.107) e
<0.001 e
168 169
0.181 (0.0124) 0.300 (0.0121)
e e
e e
e e
179 180
0.208 (0.0116) 0.300 (0.0116)
0.092 e
(0.066,0.118) e
<0.001 e
116 116
0.052 (0.0144) 0.114 (0.0145)
0.062 e
(0.030,0.094) e
<0.001 e
n 1s; ITT, intent-to-treat; LS, least squares; SE, standard error; UMEC, umeclidinium;
riod, mean baseline, and period baseline.
iod, mean baseline, period baseline, response type, and treatment by response type
monotherapy and VI monotherapy.
y and UMEC monotherapy.
J.F. Donohue et al. / Respiratory Medicine 112 (2016) 65e74703.2. 0e6 h wmFEV1 on Day 14
In the primary analysis, UMEC/VI signiﬁcantly increased the
least squares (LS) mean change from baseline in wmFEV1 0e6 h
(Day 14) versus each monotherapy in the overall ITT populations,
versus UMEC in UMEC-responders (114 mL, p < 0.001; Fig. 3a) and
versus VI in VI-responders (92 mL, p < 0.001; Fig. 3b) (Table 2). In
UMEC and VI non-responders, UMEC/VI signiﬁcantly improved
wmFEV1 0e6 h (Day 14) versus each monotherapy (70 mL versus
UMEC, p < 0.001; 62 mL versus VI, p < 0.001; Fig. 3c) (Table 2). The
LS mean change from baseline for UMEC/VI was less than fully
additive based on the monocomponent responses in both UMEC-
responders (300 mL with UMEC/VI versus 187 mL with UMEC
and 181 mL with VI) and VI-responders (300 mL with UMEC/VI
versus 163 mL with UMEC and 208 mL with VI; Table 2). Non-
responders to both monotherapies showed a LS mean change
from baseline in wmFEV1 with UMEC/VI that was numerically
lower (114mL) than that observed in the UMEC responder (300mL)
and VI-responder (300 mL) groups, but more than fully additive
based on monotherapy responses (44 mL with UMEC and 52 mL
with VI). Results were similar in the individual studies (Table A2).
In the four-subgroup post-hoc analysis, UMEC/VI signiﬁcantly
increased LS mean change from baseline inwmFEV10e6 h (Day 14)
versus either monotherapy in all subgroups (Fig. 4aed). The LS
mean change from baseline for wmFEV1 with UMEC/VI was
numerically greatest in the responders to both UMEC and VI
(372 mL), with lower changes observed in responders to VI only
(227 mL), UMEC only (229 mL) and non-responders to both UMEC
and VI (114 mL). The LS mean change from baseline for wmFEV1
with UMEC/VI was less than fully additive in responders to both
UMEC and VI, fully additive in responders to UMEC only and***
**
* **
***
***
***
***
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Fig. 4. Four-subgroup post-hoc analysis of 0e6 h wmFEV1 on Day 14 (panels aed) and tro
(panels a and e), responders to VI only (panels b and f), responders to UMEC and VI (panels
population). Grey bars represent the expected additive effect of both monotherapies (calc
monotherapies). *p ¼ 0.036 for UMEC/VI versus UMEC in responders to UMEC only (panel e
UMEC/VI versus VI in responders to VI only (panel b) and p ¼ 0.002 for UMEC/VI versus V
expiratory volume in 1s; ITT, intent-to-treat; LS, least squares; SE, standard error; UMEC, uresponders to VI only, and more than fully additive in non-
responders (Table A3).3.3. Trough FEV1 on Day 15
UMEC/VI signiﬁcantly increased the LS mean change from
baseline in trough FEV1 (Day 15) versus each monotherapy in the
overall ITT populations, versus UMEC in UMEC-responders (77 mL,
p< 0.001; Fig. 3d) and versus VI in VI-responders (86mL, p < 0.001;
Fig. 3e) (Table 3). In UMEC and VI non-responders, UMEC/VI
signiﬁcantly improved LS mean change from baseline in trough
FEV1 (Day 15) versus monotherapy (42 mL versus UMEC, p¼ 0.020;
58 mL versus VI, p ¼ 0.001; Fig. 3f) (Table 3). The LS mean change
from baseline for UMEC/VI was less than fully additive based on
monotherapy responses in both UMEC-responders (209 mL with
UMEC/VI versus 132 mL with UMEC and 112 mL with VI) and VI-
responders (220 mL with UMEC/VI versus 111 mL with UMEC and
134 mL with VI; Table 3). Non-responders to both monotherapies
showed a LS mean change from baseline with UMEC/VI that was
numerically lower (81 mL) than that observed with UMEC
responder (209 mL) and VI-responder (220 mL) groups, but more
than fully additive based on monotherapy responses (39 mL with
UMEC and 23 mL with VI). Results were similar in the individual
studies (see Supplementary Results; Table A4).
In the four-subgroup post-hoc analysis, UMEC/VI signiﬁcantly
increased LS mean change from baseline in trough FEV1 (Day 15)
versus either monotherapy in all subgroups (Fig. 4eeh). The LS
mean change from baseline for trough FEV1 with UMEC/VI was
numerically greatest in the responders to both UMEC and VI
(263 mL), with lower changes observed in responders to VI only
(177 mL), UMEC only (155 mL) and non-responders to both UMEC***
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Table 3
Analysis of trough FEV1 at Day 15 in the overall population and stratiﬁed by UMEC and VI response on Day 1, pooled analysis (ITT population).
Status UMEC
62.5mcg (n ¼ 373)
VI
25mcg (n ¼ 371)
UMEC/VI 62.5/25mcg
(n ¼ 375)
Overall populationa
n 360 362 365
LS mean change (SE) 0.091 (0.0092) 0.089 (0.0092) 0.168 (0.0091)
UMEC/VI versus monotherapy
Difference 0.077 0.080 e
(95% CI) (0.057,0.097) (0.060,0.100) e
p-value <0.001 <0.001 e
Stratiﬁed by UMEC and VI response on Day 1b
UMEC-respondersc
n 169 167 167
LS mean change (SE) 0.132 (0.0131) 0.112 (0.0132) 0.209 (0.0130)
UMEC/VI versus monotherapy
Difference 0.077 e e
(95% CI) (0.046,0.107) e e
p-value <0.001 e e
VI-respondersd
n 177 179 179
LS mean change (SE) 0.111 (0.0125) 0.134 (0.0124) 0.220 (0.0124)
UMEC/VI versus monotherapy
Difference e 0.086 e
(95% CI) e (0.057, 0.115) e
p-value e <0.001 e
Non-responders
n 115 116 115
LS mean change (SE) 0.039 (0.0154) 0.023 (0.0154) 0.081 (0.0154)
UMEC/VI versus monotherapy
Difference 0.042 0.058 e
(95% CI) (0.007, 0.078) (0.023, 0.094) e
p-value 0.020 0.001 e
ANCOVA, analysis of covariance; CI, conﬁdence interval; ITT, intent-to-treat; LS, least squares; SE, standard error; UMEC, umeclidinium; VI, vilanterol.
a Analysis performed using an ANCOVA model with covariates of study, treatment, period, mean baseline, and period baseline.
b Analysis performed using an ANCOVA model with covariates of study, treatment, period, mean baseline, period baseline, response type, and treatment by response type
interaction.
c Responder to UMEC: responder to UMEC monotherapy or responder to both UMEC monotherapy and VI monotherapy.
d Responder to VI: responder to VI monotherapy or responder to both VI monotherapy and UMEC monotherapy.
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was less than fully additive based on the monotherapy responses in
the responders to both UMEC and VI, fully additive in responders to
UMEC only and responders to VI only, and more than fully additive
in the non-responders (Table A3).
3.4. Other efﬁcacy endpoints
In the pooled analyses, a signiﬁcantly greater proportion of
patients were responsive to UMEC/VI versus UMEC or VI for each
response deﬁnition (increase from baseline of:12% and200 mL;
or 130 mL; or 100 mL) for wmFEV1 0e6 h (Day 14) and trough
FEV1 (Day 15) (Table 4). Results of these comparisons for the indi-
vidual studies were similar to the pooled analyses (Table A5).
The proportion of patients responsive to UMEC/VI, UMEC, or VI
on Day 1 (Table A6), and the proportion of patients who had a larger
change from baseline in 0e6 h wmFEV1 on Day 14 with UMEC/VI
versus each monotherapy (Table A7) are detailed in the
Supplementary Results. Serial FEV1, serial FVC and trough FVC along
with rescuemedication use (Table A8) and changes from baseline in
serial FEV1 at Day 14 (Fig. A1) are also reported in the
Supplementary Results.
3.5. Safety assessments
The overall incidence of AEs in each study was 18% for UMEC/VI,
12% and 16% for UMEC, and 15% and 18% for VI (Table A9). The most
common AEs were nasopharyngitis (1% and 4% for UMEC/VI, <1%
and 3% for UMEC, and 1% and 6% for VI in each study) and headache(5% and 3% for UMEC/VI, 2% for UMEC, and 5% and 1% for VI). All
treatments were well tolerated, with no unexpected ﬁndings re-
ported for any treatment. See Supplementary Results for serious
AEs, exacerbations, vital sign assessment, ECG and clinical labora-
tory test results.
4. Discussion
UMEC/VI 62.5/25mcg caused signiﬁcant lung function im-
provements in 0e6 h wmFEV1 (Day 14) and trough FEV1 (Day 15)
versus monotherapy in both UMEC and VI responders and non-
responders to UMEC and/or VI, but the magnitude of the beneﬁt
varied between responder groups. The absolute magnitude of lung
function improvement of UMEC/VI was greatest in patients classi-
ﬁed as responders to both UMEC and VI on Day 1 (known as dual
responders), with the lowest effect seen in non-responders to both
monocomponents. Thus, the magnitude of response to a single
long-acting bronchodilator therapy can predict the magnitude of
beneﬁt achieved from a dual bronchodilator.
The four subgroup post-hoc pooled analyses showed that the
beneﬁts of UMEC/VI over monotherapy treatment were more than
additive in non-responders to both UMEC and VI, and additive in
responders to one monotherapy only. In contrast, the effects of
UMEC/VI were less than additive in dual responders. The dose
response curve for lung function after bronchodilator use in
obstructive lung diseases follows a classical pattern with a steep
linear response followed by a plateau as themaximal possible effect
is reached [13,14]. Our data suggest that the effects of UMEC and VI
in dual responders were near the plateau of this dose response
Table 4
Analysis of proportion of responders (deﬁned as change from baseline of 12% and 200 mL, or 130 mL or 100 mL) for 0e6 h wmFEV1 at Day 14 and trough FEV1 at Day
15, pooled analysis (ITT population).
UMEC
62.5mcg (n ¼ 373)
VI
25mcg (n ¼ 371)
UMEC/VI 62.5/25mcg
(n ¼ 375)
0e6 h wmFEV1 at Day 14, change from baseline of ≥12% and ≥200 mLa
Responder 113 (31) 98 (27) 189 (52)
UMEC/VI versus monotherapy
Odds ratio 2.81 2.80 e
95% CI 2.02, 3.91 2.01, 3.92 e
p-value <0.001 <0.001 e
0e6 h wmFEV1 at Day 14, change from baseline of ≥130 mLa
Responder 177 (49) 161 (44) 241 (66)
UMEC/VI versus monotherapy
Odds ratio 2.40 2.31 e
95% CI 1.73, 3.34 1.66, 3.20 e
p-value <0.001 <0.001 e
0e6 h wmFEV1 at Day 14, change from baseline of ≥100 mLa
Responder 203 (56) 194 (54) 254 (69)
UMEC/VI versus monotherapy
Odds ratio 2.07 1.81 e
95% CI 1.48, 2.88 1.30, 2.51 e
p-value <0.001 <0.001 e
Trough FEV1 at Day 15, change from baseline of ≥12% and ≥200 mLb
Responder 98 (27) 65 (18) 144 (39)
UMEC/VI versus monotherapy
Odds ratio 2.16 2.82 e
95% CI 1.51, 3.09 1.93, 4.13 e
p-value <0.001 <0.001 e
Trough FEV1 at Day 15, change from baseline of ≥130 mLb
Responder 142 (39) 116 (32) 199 (55)
UMEC/VI versus monotherapy
Odds ratio 2.21 2.39 e
95% CI 1.59, 3.07 1.71, 3.33 e
p-value <0.001 <0.001 e
Trough FEV1 at Day 15, change from baseline of ≥100 mLb
Responder 169 (47) 136 (38) 221 (61)
UMEC/VI versus monotherapy
Odds ratio 2.03 2.43 e
95% CI 1.47, 2.81 1.75, 3.38 e
p-value <0.001 <0.001 e
Values shown for responders and non-responders are n (%).
CI, conﬁdence interval; FEV1, forced expiratory volume in 1s; ITT, intent-to-treat; UMEC, umeclidinium; VI, vilanterol; wm, weighted mean.
a n ¼ 361 (UMEC), 362 (VI), 366 (UMEC/VI).
b n ¼ 360 (UMEC), 362 (VI), 365 (UMEC/VI).
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For non-responders to both UMEC and VI, the change from
baseline of either monotherapy alone (pooled analysis) on 0e6 h
wmFEV1 at Day 14 and trough FEV1 at Day 15 were <60 mL and
<40 mL, respectively. These effects are well below the published
minimally clinically important difference (MCID) for FEV1, which is
approximately 100 mL [15]. UMEC/VI treatment in these patients
caused increases in FEV1 that were numerically greater than the
sum of the monocomponent effects, with 114 mL and 81 mL im-
provements observed for 0e6 h wmFEV1 and trough FEV1,
respectively. These changes with UMEC/VI were around the level of
the MCID, while the monotherapy responses were not. While these
lung function changes were smaller than the other (responder)
subgroups, it is known that the magnitude of change in FEV1 is
weakly correlatedwith clinical outcomes such as exacerbations and
health status [16,17], and a small lung function improvement may
still improve clinical symptoms. Changes in FEV1 are smaller in
patients with more severe disease [18], which may also contribute
to this observation. Overall, these results indicate that UMEC/VI
therapy may be of beneﬁt to patients in clinical practice who have
not previously responded well to long-acting bronchodilator
monotherapy.
Our data suggests a more than additive phenomenon of
UMEC/VI in patients who are non-responders to monotherapy. The
mechanisms behind this observationwere not investigated in thesestudies. However it has been previously shown in isolated human
airway muscle that the addition of a beta-agonists decreases the
release of acetylcholine from post-ganglionic cholinergic nerve
endings by stimulating pre-synaptic beta-receptors on para-
sympathetic ganglia, resulting in inhibition of cholinergic neuro-
transmission [19]. Experiments involving rat and guinea pig
isolated tracheae indicate that this process may involve the release
of inhibitory prostaglandins from airway mucosa [20], thereby
amplifying the smooth muscle relaxation induced by muscarinic
antagonists. Secondly, direct measurements of patient intra-
bronchial pressure with a catheter tip micromanometer show
that beta-agonists appear to have a greater effect than muscarinic
antagonists on peripheral airways whereas inhaled muscarinic
antagonists are more likely to act on central airways that are
abundantly innervated by parasympathetic nerves [21]. It is
therefore possible that the bronchodilator response observed with
UMEC/VI is maximised by the different preferential sites of action
of beta-agonists and muscarinic antagonists, in addition to their
distinctmechanisms of action. Further investigations to understand
this observation with UMEC/VI are of clinical interest.
Deﬁning the most appropriate treatment regimen for individual
patients is of clinical interest. Previous reports have shown that
several LAMA/LABA combinations signiﬁcantly improve lung
function versus monocomponents in patients with COPD
[5,7,22e24]. These parallel group studies evaluated efﬁcacy in
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study now demonstrates that response to a single dose of long-
acting bronchodilator can predict different patterns of response
to combination therapy.
Our studies used a well-established design to evaluate short-
term efﬁcacy/safety of bronchodilators. Results were qualitatively
similar between the studies; although, the magnitude of im-
provements was variable. UMEC and VI monotherapy and UMEC/VI
were well tolerated in both studies, and the AE proﬁles were
consistent with previous 12- or 24-week studies in patients with
COPD [6e8,25].
A key strength of these studies is the complete block, cross-
over design allowing evaluation of within-patient responses to
multiple study treatments. Other strengths include: broad inclu-
sion criteria (FEV1  70%); large sample sizes; identical designs
enabling pooled analyses; use of clinical doses of once-daily UMEC
(62.5mcg) and UMEC/VI (62.5/25mcg); and very high compliance
with study medication. Potential limitations include: responder
status classiﬁed on Day 1 using an arbitrary deﬁnition of increase
from baseline in FEV1 of 12% and 200 mL (this measurement is
known to vary between visits [26]); short treatment duration; and
the studies not being designed to properly assess endpoints such
as symptoms.
In conclusion, these studies demonstrated that themagnitude of
improvement in lung function on UMEC/VI versus monotherapy
after 14 days varied according to monotherapy response on Day 1.
Improvement was greatest amongst patients who responded to
UMEC or VI. A second important ﬁnding of particular clinical rele-
vance was that non-responders to both UMEC and VI monotherapy
achieved a clinically meaningful lung function response when
UMEC/VI was administered. In these patients, response to UMEC/VI
was more than the additive effect of the monotherapies.
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